VSTM Key Statistics, Chart & Performance
The current stock price of VSTM is 7.72 USD. In the past month the price decreased by -21.06%. In the past year, price increased by 10.29%.
VSTM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About VSTM
Company Profile
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Company Info
VERASTEM INC
117 Kendrick Street, Suite 500
Needham MASSACHUSETTS 02494 US
CEO: Brian M. Stuglik
Employees: 78
Phone: 17812924200
VERASTEM INC / VSTM FAQ
Can you describe the business of VERASTEM INC?
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
What is the current price of VSTM stock?
The current stock price of VSTM is 7.72 USD. The price increased by 2.39% in the last trading session.
Does VSTM stock pay dividends?
VSTM does not pay a dividend.
What is the ChartMill technical and fundamental rating of VSTM stock?
VSTM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for VERASTEM INC?
VERASTEM INC (VSTM) operates in the Health Care sector and the Biotechnology industry.
What is VERASTEM INC worth?
VERASTEM INC (VSTM) has a market capitalization of 595.60M USD. This makes VSTM a Small Cap stock.
VSTM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM turns out to be only a medium performer in the overall market: it outperformed 40.84% of all stocks.
VSTM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VSTM. Both the profitability and financial health of VSTM have multiple concerns.
VSTM Financial Highlights
Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS decreased by -21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VSTM Forecast & Estimates
15 analysts have analysed VSTM and the average price target is 16.32 USD. This implies a price increase of 111.4% is expected in the next year compared to the current price of 7.72.
For the next year, analysts expect an EPS growth of 8.17% and a revenue growth 237.98% for VSTM